Abstract
Background: There is growing interest for identification of new targets for biomarker development in multiple sclerosis (MS). The goal of this study was to compare the concentration and the methylation patterns of cell-free plasma DNA (cfpDNA) in patients with relapsing-remitting multiple sclerosis (RRMS) and healthy individuals. Methods: Three 30-patient cohorts were examined: patients with RRMS, in either remission or exacerbation, and healthy individuals as controls. Concentration of cfpDNA was determined using a standard fluorometric assay. Patterns of methylation in 56 gene promoters were determined by a microarray-based assay (MethDet-56). The data were analyzed to identify statistically relevant differences among the study groups. Results: The concentration of cfpDNA in patients with RRMS was four to eight-fold higher compared to healthy controls. Significant differences in cfpDNA methylation patterns were detected in all three comparisons: RRMS patients in remission versus healthy controls were recognized with 79.2% sensitivity and 92.9% specificity; RRMS patients in exacerbation versus healthy controls were recognized with 75.9% sensitivity and 91.5% specificity; and RRMS patients in exacerbation versus those in remission were recognized with 70.8% sensitivity and 71.2% specificity. Conclusion: Based on our findings, we conclude that patients with RRMS display unique disease- and state-specific changes of cfpDNA. Our findings are of clinical significance as they could be used in the development of potentially new biomarkers for MS. This is the first report in our knowledge describing such changes of cfpDNA in patients with MS.
Original language | English (US) |
---|---|
Pages (from-to) | 16-21 |
Number of pages | 6 |
Journal | Journal of the Neurological Sciences |
Volume | 290 |
Issue number | 1-2 |
DOIs | |
State | Published - Mar 15 2010 |
Funding
The project was supported by the NS060311 grant from NINDS (VL) and philanthropy to the Rush University MS Center (RB, DS). Authors are grateful to Melinda Kopec, R.N., Cynthia Dendrinos, R.N., Carmen Petrizzo, R.N. and Raquel Brillante, N.P., for their invaluable help with the collection of blood samples and clinical data. VL is grateful to Dr. John Flax (PrecisionMed, Inc.) for a subset of plasma samples, and to Dr. Joel Peek (Microarrays, Inc.) for printing microarrays and technical support with microarray experiments.
Keywords
- Biomarker
- Cell-free plasma DNA
- DNA methylation
- Gene promoter
- Microarray
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Neurology